Literature DB >> 19772876

Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge.

Zhiyuan Wen1, Ling Ye, Yulong Gao, Lei Pan, Ke Dong, Zhigao Bu, Richard W Compans, Chinglai Yang.   

Abstract

Influenza virus-like particles (VLPs) were produced in Sf9 insect cells by co-expressing the matrix protein M1 and the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) using the recombinant baculovirus expression system. The VLPs were morphologically similar to influenza virions. Both HA and NA proteins were incorporated into VLPs and these proteins retained their functional activities. Further, influenza VLPs but not inactivated influenza viruses (IIV) stimulated secretion of inflammatory cytokines from mouse bone marrow-derived dendritic cells (BMDC). Immunogenicity of influenza VLPs and their protective efficacies against lethal influenza virus challenge were evaluated in young and aged mice. Immunization with influenza VLPs induced strong antibody responses against HA that inhibited hemagglutination by influenza virus, similar to IIV vaccines. Compared to young mice, antibody responses in aged mice immunized with a low dose of either influenza VLPs or IIV vaccines exhibited markedly reduced avidity for HA. However, immunization of aged mice with a high dose of influenza VLPs induced antibody responses with high avidity similar to those in young mice. Furthermore, all vaccinated animals survived a lethal challenge by a mouse-adapted influenza virus (A/PR/8/34), indicating that influenza VLPs are highly efficacious for protection against influenza virus infection in both young and aged mice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19772876      PMCID: PMC2787645          DOI: 10.1016/j.antiviral.2009.09.005

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  61 in total

1.  Plasmid-driven formation of influenza virus-like particles.

Authors:  G Neumann; T Watanabe; Y Kawaoka
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 2.  Immunity to influenza in the elderly.

Authors:  R G Webster
Journal:  Vaccine       Date:  2000-02-25       Impact factor: 3.641

3.  Enhanced immune responses and resistance against infection in aged mice conferred by Flu-ISCOMs vaccine correlate with up-regulation of costimulatory molecule CD86.

Authors:  S Sambhara; A Kurichh; R Miranda; A Tamane; R Arpino; O James; U McGuinness; A Kandil; B Underdown; M Klein; D Burt
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

Review 4.  Immunosenescence and germinal center reaction.

Authors:  B Zheng; S Han; Y Takahashi; G Kelsoe
Journal:  Immunol Rev       Date:  1997-12       Impact factor: 12.988

Review 5.  The Th1/Th2 paradigm.

Authors:  S Romagnani
Journal:  Immunol Today       Date:  1997-06

Review 6.  The socio-economic burden of influenza.

Authors:  T Szucs
Journal:  J Antimicrob Chemother       Date:  1999-11       Impact factor: 5.790

7.  Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.

Authors:  Jose M Galarza; Theresa Latham; Albert Cupo
Journal:  Viral Immunol       Date:  2005       Impact factor: 2.257

8.  Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus.

Authors:  Z Sha; R W Compans
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

9.  A nonionic block co-polymer adjuvant (CRL1005) enhances the immunogenicity and protective efficacy of inactivated influenza vaccine in young and aged mice.

Authors:  J M Katz; X Lu; C W Todd; M J Newman
Journal:  Vaccine       Date:  2000-04-28       Impact factor: 3.641

10.  Immunogenicity and efficacy of DNA vaccines encoding influenza A proteins in aged mice.

Authors:  B S Bender; J B Ulmer; C M DeWitt; R Cottey; S F Taylor; A M Ward; A Friedman; M A Liu; J J Donnelly
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

View more
  18 in total

1.  Designing Two Individual AcMNPV Polyhedrin-Plus Bac-to-Bac Expression System in order to Express GFP and CPV-VP2 in Insect Cells.

Authors:  Mohammad Sadegh Hashemzadeh; Seyed Jafar Mousavy; Ruhollah Dorostkar; Fatemeh Fotouhi; Firouz Ebrahimi
Journal:  Iran J Biotechnol       Date:  2017-09-27       Impact factor: 1.671

2.  Enhanced Stability of Inactivated Influenza Vaccine Encapsulated in Dissolving Microneedle Patches.

Authors:  Leonard Y Chu; Ling Ye; Ke Dong; Richard W Compans; Chinglai Yang; Mark R Prausnitz
Journal:  Pharm Res       Date:  2015-12-01       Impact factor: 4.200

3.  Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus.

Authors:  Timothy Sheahan; Alan Whitmore; Kristin Long; Martin Ferris; Barry Rockx; William Funkhouser; Eric Donaldson; Lisa Gralinski; Martha Collier; Mark Heise; Nancy Davis; Robert Johnston; Ralph S Baric
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

4.  Glucan supplementation enhances the immune response against an influenza challenge in mice.

Authors:  Vaclav Vetvicka; Jana Vetvickova
Journal:  Ann Transl Med       Date:  2015-02

5.  NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge.

Authors:  Natalie Pica; Ryan A Langlois; Florian Krammer; Irina Margine; Peter Palese
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

6.  Blockage of regulatory T cells augments induction of protective immune responses by influenza virus-like particles in aged mice.

Authors:  Zhiyuan Wen; Xi Wang; Ke Dong; Huizhong Zhang; Zhigao Bu; Ling Ye; Chinglai Yang
Journal:  Microbes Infect       Date:  2017-09-09       Impact factor: 2.700

7.  Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus.

Authors:  Gopi S Mohan; Wenfang Li; Ling Ye; Richard W Compans; Chinglai Yang
Journal:  PLoS Pathog       Date:  2012-12-13       Impact factor: 6.823

8.  Characterization of immune responses induced by immunization with the HA DNA vaccines of two antigenically distinctive H5N1 HPAIV isolates.

Authors:  Yulong Gao; Zhiyuan Wen; Ke Dong; Gongxun Zhong; Xiaomei Wang; Zhigao Bu; Hualan Chen; Ling Ye; Chinglai Yang
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

9.  Hyper-enhanced production of foreign recombinant protein by fusion with the partial polyhedrin of nucleopolyhedrovirus.

Authors:  Sung Min Bae; Hee Jung Kim; Jun Beom Lee; Jae Bang Choi; Tae Young Shin; Hyun Na Koo; Jae Young Choi; Kwang Sik Lee; Yeon Ho Je; Byung Rae Jin; Sung Sik Yoo; Soo Dong Woo
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

Review 10.  Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches.

Authors:  Christine M Thompson; Emma Petiot; Alexandre Lennaertz; Olivier Henry; Amine A Kamen
Journal:  Virol J       Date:  2013-05-04       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.